

Michele Emdin

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6482638/publications.pdf>

Version: 2024-02-01

400
papers

11,682
citations

26567

56
h-index

53109

85
g-index

424
all docs

424
docs citations

424
times ranked

11791
citing authors

#	ARTICLE	IF	CITATIONS
1	Protecting higher education institutions from COVID-19: insights from an Italian experience. <i>Journal of American College Health</i> , 2022, 70, 1354-1355.	0.8	21
2	Preventing heart failure: a position paper of the Heart Failure Association in collaboration with the European Association of Preventive Cardiology. <i>European Journal of Preventive Cardiology</i> , 2022, 29, 275-300.	0.8	11
3	Biomarkers for the diagnosis and management of heart failure. <i>Heart Failure Reviews</i> , 2022, 27, 625-643.	1.7	135
4	A national survey on prevalence of possible echocardiographic red flags of amyloid cardiomyopathy in consecutive patients undergoing routine echocardiography: study design and patients characterization – the first insight from the AC-TIVE Study. <i>European Journal of Preventive Cardiology</i> , 2022, 29, e173-e177.	0.8	21
5	The triglyceride/HDL cholesterol ratio and TyG index predict coronary atherosclerosis and outcome in the general population. <i>European Journal of Preventive Cardiology</i> , 2022, 29, e203-e204.	0.8	4
6	Creatine deficiency and heart failure. <i>Heart Failure Reviews</i> , 2022, 27, 1605-1616.	1.7	13
7	Pirfenidone as a novel cardiac protective treatment. <i>Heart Failure Reviews</i> , 2022, 27, 525-532.	1.7	19
8	Restrictive spirometry pattern and abnormal cardiopulmonary response to exercise in transthyretin cardiac amyloidosis. <i>European Respiratory Journal</i> , 2022, 59, 2102838.	3.1	6
9	Prognostic Benefit of New Drugs for HFrEF: A Systematic Review and Network Meta-Analysis. <i>Journal of Clinical Medicine</i> , 2022, 11, 348.	1.0	5
10	High-sensitivity troponins for outcome prediction in the general population: a systematic review and meta-analysis. <i>European Journal of Internal Medicine</i> , 2022, 98, 61-68.	1.0	15
11	Preventing heart failure: a position paper of the Heart Failure Association in collaboration with the European Association of Preventive Cardiology. <i>European Journal of Heart Failure</i> , 2022, 24, 143-168.	2.9	41
12	Echocardiographic Biventricular Coupling Index to Predict Precapillary Pulmonary Hypertension. <i>Journal of the American Society of Echocardiography</i> , 2022, 35, 715-726.	1.2	6
13	Cardiac remodelling – Part 1: From cells and tissues to circulating biomarkers. A review from the Study Group on Biomarkers of the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2022, 24, 927-943.	2.9	29
14	Multi-chamber speckle tracking imaging and diagnostic value of left atrial strain in cardiac amyloidosis. <i>European Heart Journal Cardiovascular Imaging</i> , 2022, 24, 130-141.	0.5	18
15	Cardiac protection by pirfenidone after myocardial infarction: a bioinformatic analysis. <i>Scientific Reports</i> , 2022, 12, 4691.	1.6	4
16	In Vivo Murine Models of Cardiotoxicity Due to Anticancer Drugs: Challenges and Opportunities for Clinical Translation. <i>Journal of Cardiovascular Translational Research</i> , 2022, , 1.	1.1	2
17	Central Apneas Are More Detrimental in Female Than in Male Patients With Heart Failure. <i>Journal of the American Heart Association</i> , 2022, 11, e024103.	1.6	7
18	Urinary NGAL in acute heart failure revisited: the game is not over yet. <i>International Journal of Cardiology</i> , 2022, 357, 113-114.	0.8	2

#	ARTICLE	IF	CITATIONS
19	RNA-targeting and gene editing therapies for transthyretin amyloidosis. <i>Nature Reviews Cardiology</i> , 2022, 19, 655-667.	6.1	64
20	Critical Comparison of Documents From Scientific Societies on Cardiac Amyloidosis. <i>Journal of the American College of Cardiology</i> , 2022, 79, 1288-1303.	1.2	35
21	Response to the Letter: Sleep-Disordered Breathing in Precapillary Pulmonary Hypertension: Is the Prevalence So High? Reference Article: Sleep-Disordered Breathing and Nocturnal Hypoxemia in Precapillary Pulmonary Hypertension: Prevalence, Pathophysiological Determinants and Clinical Consequences by Zheng Z et al., <i>Respiration</i> , 2022, 101, 433-435.	1.2	1
22	Is targeting cyclic guanosine monophosphate by vericiguat effective to treat ischaemic heart failure with reduced ejection fraction? Yes, it is. <i>European Journal of Heart Failure</i> , 2022, 24, 791-793.	2.9	1
23	Pirfenidone for Idiopathic Pulmonary Fibrosis and Beyond. <i>Cardiac Failure Review</i> , 2022, 8, e12.	1.2	19
24	Targeting precipitants to prevent heart failure hospitalization. Does season matter?. <i>International Journal of Cardiology</i> , 2022, , .	0.8	0
25	The revolution of ATTR amyloidosis in cardiology: certainties, gray zones and perspectives. <i>Minerva Cardiology and Angiology</i> , 2022, 70, 248-257.	0.4	2
26	Management of heart failure with preserved ejection fraction: from neurohormonal antagonists to empagliflozin. <i>Heart Failure Reviews</i> , 2022, , .	1.7	5
27	Cardiac remodelling Part 2: Clinical, imaging and laboratory findings. A review from the Study Group on Biomarkers of the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2022, 24, 944-958.	2.9	22
28	Redefining the epidemiology of cardiac amyloidosis. A systematic review and meta-analysis of screening studies. <i>European Journal of Heart Failure</i> , 2022, 24, 2342-2351.	2.9	51
29	Old and new equations for maximal heart rate prediction in patients with heart failure and reduced ejection fraction on beta-blockers treatment: results from the MECKI score data set. <i>European Journal of Preventive Cardiology</i> , 2022, 29, 1680-1688.	0.8	11
30	Relative Efficacy of Sacubitril-Valsartan, Vericiguat, and SGLT2 Inhibitors in Heart Failure with Reduced Ejection Fraction: a Systematic Review and Network Meta-Analysis. <i>Cardiovascular Drugs and Therapy</i> , 2021, 35, 1067-1076.	1.3	40
31	Daptomycin-based aminoglycoside-sparing therapy for streptococcal endocarditis: a retrospective multicenter study. <i>Journal of Chemotherapy</i> , 2021, 33, 435-439.	0.7	2
32	Colchicine for the treatment of coronary artery disease. <i>Trends in Cardiovascular Medicine</i> , 2021, 31, 497-504.	2.3	10
33	Cardiac magnetic resonance in patients with muscular dystrophies. <i>European Journal of Preventive Cardiology</i> , 2021, 28, 1526-1535.	0.8	11
34	Amiodarone as a possible therapy for coronavirus infection. <i>European Journal of Preventive Cardiology</i> , 2021, 28, e16-e18.	0.8	27
35	Management of complications of cardiac amyloidosis: 10 questions and answers. <i>European Journal of Preventive Cardiology</i> , 2021, 28, 1000-1005.	0.8	12
36	Medication Reconciliation During Hospitalization and in Hospital-Home Interface: An Observational Retrospective Study. <i>Journal of Patient Safety</i> , 2021, 17, e143-e148.	0.7	5

#	ARTICLE	IF	CITATIONS
37	The value of hospital personnel serological screening in an integrated COVID-19 infection prevention and control strategy. <i>Infection Control and Hospital Epidemiology</i> , 2021, 42, 373-374.	1.0	11
38	Prognostic value of implantable defibrillatorâ€œcomputed respiratory disturbance index: The DASAP-HF study. <i>Heart Rhythm</i> , 2021, 18, 374-381.	0.3	2
39	[18F]-Florbetaben PET/CT for Differential Diagnosis Among Cardiac Immunoglobulin Light Chain, Transthyretin Amyloidosis, andâ€œMimicking Conditions. <i>JACC: Cardiovascular Imaging</i> , 2021, 14, 246-255.	2.3	51
40	Prognostic value of cardiopulmonary exercise testing in cardiac amyloidosis. <i>European Journal of Heart Failure</i> , 2021, 23, 231-239.	2.9	26
41	Arterial thrombo-embolic events in cardiac amyloidosis: a look beyond atrial fibrillation. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2021, 28, 12-18.	1.4	38
42	Effect of lowâ€œdose colchicine in acute and chronic coronary syndromes: A systematic review and metaâ€œanalysis. <i>European Journal of Clinical Investigation</i> , 2021, 51, e13464.	1.7	24
43	A simple echocardiographic score to rule out cardiac amyloidosis. <i>European Journal of Clinical Investigation</i> , 2021, 51, e13449.	1.7	24
44	Renin profiling predicts neurohormonal response to sacubitril/valsartan. <i>ESC Heart Failure</i> , 2021, 8, 719-724.	1.4	3
45	Effects of nasal high flow on sympathovagal balance, sleep, and sleep-related breathing in patients with precapillary pulmonary hypertension. <i>Sleep and Breathing</i> , 2021, 25, 705-717.	0.9	2
46	Sleep-Disordered Breathing and Nocturnal Hypoxemia in Precapillary Pulmonary Hypertension: Prevalence, Pathophysiological Determinants, and Clinical Consequences. <i>Respiration</i> , 2021, 100, 865-876.	1.2	15
47	Tafamidis is entering the clinical arena for the treatment of transthyretinâ€œrelated cardiomyopathy: certainties and unmet needs. <i>European Journal of Heart Failure</i> , 2021, 23, 286-289.	2.9	1
48	Morphologies and prognostic significance of left ventricular volume/time curves with cardiac magnetic resonance in patients with non-ischæmic heart failure and left bundle branch block. <i>International Journal of Cardiovascular Imaging</i> , 2021, 37, 2245-2255.	0.7	6
49	Breath-hold task induces temporal heterogeneity in electroencephalographic regional field power in healthy subjects. <i>Journal of Applied Physiology</i> , 2021, 130, 298-307.	1.2	1
50	Use of biomarkers to diagnose and manage cardiac amyloidosis. <i>European Journal of Heart Failure</i> , 2021, 23, 217-230.	2.9	33
51	Deep-learning-based cardiac amyloidosis classification from early acquired pet images. <i>International Journal of Cardiovascular Imaging</i> , 2021, 37, 2327-2335.	0.7	16
52	A novel echocardiographic method for estimation of pulmonary artery wedge pressure and pulmonary vascular resistance. <i>ESC Heart Failure</i> , 2021, 8, 1216-1229.	1.4	22
53	Biopsy Evidence of Sequential Transthyretin and Immunoglobulin Light-Chain Cardiac Amyloidosis in the Same Patient. <i>JACC: Case Reports</i> , 2021, 3, 450-454.	0.3	2
54	Overlapping Effects of miR-21 Inhibition and Drugs for Idiopathic Pulmonary Fibrosis: Rationale for Repurposing Nintedanib as a Novel Treatment for Ischemia/Reperfusion Injury. <i>Journal of Cardiovascular Pharmacology</i> , 2021, 77, 332-333.	0.8	2

#	ARTICLE	IF	CITATIONS
55	Re-appraisal of the obesity paradox in heart failure: a meta-analysis of individual data. <i>Clinical Research in Cardiology</i> , 2021, 110, 1280-1291.	1.5	20
56	Central apneas, chemoreflex sensitivity, and buspirone in spinal cord injury: a word of caution. <i>Journal of Applied Physiology</i> , 2021, 130, 756-757.	1.2	1
57	How much is it to mend a broken heart? Results from the US Nationwide Readmission Database. <i>International Journal of Cardiology</i> , 2021, 329, 150-151.	0.8	2
58	Post-mortem CMR in a model of sudden death due to myocardial ischemia: validation with connexin-43. <i>European Radiology</i> , 2021, 31, 8098-8107.	2.3	5
59	Quality of life assessment in amyloid transthyretin (ATTR) amyloidosis. <i>European Journal of Clinical Investigation</i> , 2021, 51, e13598.	1.7	16
60	Prognostic value of reverse remodelling criteria in heart failure with reduced or mid-range ejection fraction. <i>ESC Heart Failure</i> , 2021, 8, 3014-3025.	1.4	11
61	Sacubitril-valsartan treatment is associated with decrease in central apneas in patients with heart failure with reduced ejection fraction. <i>International Journal of Cardiology</i> , 2021, 330, 112-119.	0.8	14
62	Cocaine and methamphetamine use and hospitalization for acute heart failure: Epidemiological evidence from a nationwide dataset. <i>International Journal of Cardiology</i> , 2021, 333, 141-142.	0.8	1
63	Indications of beta-adrenoceptor blockers in Takotsubo syndrome and theoretical reasons to prefer agents with vasodilating activity. <i>International Journal of Cardiology</i> , 2021, 333, 45-50.	0.8	11
64	Molecular Autopsy of Sudden Cardiac Death in the Genomics Era. <i>Diagnostics</i> , 2021, 11, 1378.	1.3	16
65	The "Peptide for Life"™ Initiative: a call for action to provide equal access to the use of natriuretic peptides in the diagnosis of acute heart failure across Europe. <i>European Journal of Heart Failure</i> , 2021, 23, 1432-1436.	2.9	10
66	The place of vericiguat in the landscape of treatment for heart failure with reduced ejection fraction. <i>Heart Failure Reviews</i> , 2021, , 1.	1.7	9
67	The ergoreflex: how the skeletal muscle modulates ventilation and cardiovascular function in health and disease. <i>European Journal of Heart Failure</i> , 2021, 23, 1458-1467.	2.9	29
68	Vericiguat for Heart Failure with Reduced Ejection Fraction. <i>Current Cardiology Reports</i> , 2021, 23, 144.	1.3	19
69	Discharge FGF23 level predicts one year outcome in patients admitted with acute heart failure. <i>International Journal of Cardiology</i> , 2021, 336, 98-104.	0.8	6
70	Novel Drug Targets for Central Apneas in Heart Failure: On the Road. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021, 204, 490-491.	2.5	0
71	The Role of 18FDG PET/CT in the Assessment of Endocarditis, Myocarditis and Pericarditis. <i>Current Radiopharmaceuticals</i> , 2021, 14, 259-272.	0.3	1
72	Patients with cardiac amyloidosis have a greater neurohormonal activation than those with non-amyloidotic heart failure. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2021, 28, 252-258.	1.4	9

#	ARTICLE	IF	CITATIONS
73	CMR predictors of secondary moderate to severe mitral regurgitation and its additive prognostic role in previous myocardial infarction. <i>Journal of Cardiology</i> , 2021, 79, 90-97.	0.8	0
74	Integration of imaging and circulating biomarkers in heart failure: a consensus document by the Biomarkers and Imaging Study Groups of the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2021, 23, 1577-1596.	2.9	23
75	Sex-related differences in ventricular remodeling after myocardial infarction. <i>International Journal of Cardiology</i> , 2021, 339, 62-69.	0.8	11
76	Mapping dependencies of BOLD signal change to end-tidal CO ₂ : Linear and nonlinear modeling, and effect of physiological noise correction. <i>Journal of Neuroscience Methods</i> , 2021, 362, 109317.	1.3	1
77	Hide and seek. Ticagrelor and central apneas after acute coronary syndrome. <i>Sleep Medicine</i> , 2021, 86, 125.	0.8	0
78	Benefit of buspirone on chemoreflex and central apnoeas in heart failure: a randomized controlled crossover trial. <i>European Journal of Heart Failure</i> , 2021, 23, 312-320.	2.9	28
79	Oxidative stress and inflammation: determinants of anthracycline cardiotoxicity and possible therapeutic targets. <i>Heart Failure Reviews</i> , 2021, 26, 881-890.	1.7	43
80	Imaging predictors of incident heart failure: a systematic review and meta-analysis. <i>Journal of Cardiovascular Medicine</i> , 2021, 22, 378-387.	0.6	7
81	Amyloid Deposits and Fibrosis on Left Ventricular Endomyocardial Biopsy Correlate With Extracellular Volume in Cardiac Amyloidosis. <i>Journal of the American Heart Association</i> , 2021, 10, e020358.	1.6	34
82	Remote Ischemic Conditioning in Ischemic Stroke and Myocardial Infarction: Similarities and Differences. <i>Frontiers in Neurology</i> , 2021, 12, 716316.	1.1	6
83	Cardiac biomarkers retain prognostic significance in patients with heart failure and chronic obstructive pulmonary disease. <i>Journal of Cardiovascular Medicine</i> , 2021, Publish Ahead of Print, 28-36.	0.6	1
84	APAP therapy does not improve impaired sleep quality and sympatho-vagal balance: a randomized trial in patients with obstructive sleep apnea and systolic heart failure. <i>Sleep and Breathing</i> , 2020, 24, 211-219.	0.9	10
85	Validity of transit time-based blood pressure measurements in patients with and without heart failure or pulmonary arterial hypertension across different breathing maneuvers. <i>Sleep and Breathing</i> , 2020, 24, 221-230.	0.9	5
86	Cardiac amyloidosis: The starched heart. <i>Journal of Nuclear Cardiology</i> , 2020, 27, 133-136.	1.4	7
87	Keys to early diagnosis of cardiac amyloidosis: red flags from clinical, laboratory and imaging findings. <i>European Journal of Preventive Cardiology</i> , 2020, 27, 1806-1815.	0.8	60
88	How a large registry can explain pathophysiology: The case of anemia in the heart failure syndromes. <i>International Journal of Cardiology</i> , 2020, 298, 72-73.	0.8	0
89	Procalcitonin, white blood cell count and C-reactive protein as predictors of <i>S. aureus</i> infection and mortality in infective endocarditis. <i>International Journal of Cardiology</i> , 2020, 301, 190-194.	0.8	22
90	Oxidative stress and inflammation in the evolution of heart failure: From pathophysiology to therapeutic strategies. <i>European Journal of Preventive Cardiology</i> , 2020, 27, 494-510.	0.8	142

#	ARTICLE	IF	CITATIONS
91	Scoring frailty in patients hospitalized for heart failure: Impact on prognosis (and decision making.) Tj ETQq1 1 0.784314 rgBJ /Overl	0.8	14
92	Highly Elevated Plasma γ -Glutamyltransferase Elevations: A Trait Caused by γ -Glutamyltransferase 1 Transmembrane Mutations. Hepatology, 2020, 71, 1124-1127.	3.6	4
93	Circulating levels and prognostic value of soluble ST2 in heart failure are less influenced by age than N-terminal pro-B-type natriuretic peptide and high-sensitivity troponin T. European Journal of Heart Failure, 2020, 22, 2078-2088.	2.9	26
94	Multiparametric Echocardiography Scores for the Diagnosis of Cardiac Amyloidosis. JACC: Cardiovascular Imaging, 2020, 13, 909-920.	2.3	136
95	Biomarker-guided management in acute heart failure: is there light at the end of the tunnel?. European Journal of Heart Failure, 2020, 22, 276-278.	2.9	2
96	Biomarkers for growth prediction of abdominal aortic aneurysm: A step forward(?). European Journal of Preventive Cardiology, 2020, 27, 130-131.	0.8	3
97	Increased serum uric acid level predicts poor prognosis in mildly severe chronic heart failure with reduced ejection fraction. An analysis from the MECKI score research group. European Journal of Internal Medicine, 2020, 72, 47-52.	1.0	15
98	N-Terminal Pro-B-Type Natriuretic Peptide and Clinical Outcomes. JACC: Heart Failure, 2020, 8, 931-939.	1.9	88
99	Targeting Cyclic Guanosine Monophosphate to Treat Heart Failure. Journal of the American College of Cardiology, 2020, 76, 1795-1807.	1.2	71
100	Abdominal Fat Biopsy for the Diagnosis of Cardiac Amyloidosis. JACC: Case Reports, 2020, 2, 1182-1185.	0.3	3
101	Research protocol for the validation of a new portable technology for real-time continuous monitoring of Early Warning Score (EWS) in hospital practice and for an early-stage multistakeholder assessment. BMJ Open, 2020, 10, e040738.	0.8	3
102	Searching for diagnostic biomarkers of heart failure with preserved ejection fraction: methodological issues. European Journal of Heart Failure, 2020, 22, 1598-1599.	2.9	3
103	Reply. Journal of the American College of Cardiology, 2020, 76, 2040-2041.	1.2	0
104	Late gadolinium enhancement role in arrhythmic risk stratification of patients with LMNA cardiomyopathy: results from a long-term follow-up multicentre study. Europace, 2020, 22, 1864-1872.	0.7	21
105	Atypical Progeroid Syndrome and Partial Lipodystrophy Due to LMNA Gene p.R349W Mutation. Journal of the Endocrine Society, 2020, 4, bvaa108.	0.1	8
106	Deep learning to diagnose cardiac amyloidosis from cardiovascular magnetic resonance. Journal of Cardiovascular Magnetic Resonance, 2020, 22, 84.	1.6	33
107	Scared to Death. JACC: Case Reports, 2020, 2, 2400-2403.	0.3	4
108	The unbearable underreporting of comorbidities in heart failure clinical trials. European Journal of Heart Failure, 2020, 22, 1043-1044.	2.9	5

#	ARTICLE	IF	CITATIONS
109	Cardiovascular disease and COVID-19: les liaisons dangereuses. <i>European Journal of Preventive Cardiology</i> , 2020, 27, 1017-1025.	0.8	27
110	Wild type transthyretin amyloidosis: Don't miss diagnosis!. <i>International Journal of Cardiology</i> , 2020, 312, 96-97.	0.8	3
111	Safety and Tolerability of Neurohormonal Antagonism in Cardiac Amyloidosis. <i>European Journal of Internal Medicine</i> , 2020, 80, 66-72.	1.0	34
112	Upright Cheyne-Stokes Respiration in Patients With Heart Failure. <i>Journal of the American College of Cardiology</i> , 2020, 75, 2934-2946.	1.2	31
113	COVID-19 and risk of pulmonary fibrosis: the importance of planning ahead. <i>European Journal of Preventive Cardiology</i> , 2020, 27, 1442-1446.	0.8	69
114	Safety and efficacy of levosimendan in patients with cardiac amyloidosis. <i>European Journal of Internal Medicine</i> , 2020, 80, 114-116.	1.0	3
115	Neprilysin inhibition, endorphin dynamics, and early symptomatic improvement in heart failure: a pilot study. <i>ESC Heart Failure</i> , 2020, 7, 559-566.	1.4	15
116	Unveiling a sudden unexplained death case by whole exome sequencing and bioinformatic analysis. <i>Molecular Genetics & Genomic Medicine</i> , 2020, 8, e1182.	0.6	6
117	The extent and location of late gadolinium enhancement predict defibrillator shock and cardiac mortality in patients with non-ischaemic dilated cardiomyopathy. <i>International Journal of Cardiology</i> , 2020, 307, 180-186.	0.8	14
118	Pirfenidone is a cardioprotective drug: Mechanisms of action and preclinical evidence. <i>Pharmacological Research</i> , 2020, 155, 104694.	3.1	52
119	Î±1 Antitrypsin as a potential biomarker in chronic heart failure. <i>Journal of Cardiovascular Medicine</i> , 2020, 21, 209-215.	0.6	3
120	Diphosphonate single-photon emission computed tomography in cardiac transthyretin amyloidosis. <i>International Journal of Cardiology</i> , 2020, 307, 187-192.	0.8	9
121	Omics phenotyping in heart failure: the next frontier. <i>European Heart Journal</i> , 2020, 41, 3477-3484.	1.0	48
122	Adaptive servo-ventilation therapy does not favourably alter sympatho-vagal balance in sleeping patients with systolic heart failure and central apnoeas: Preliminary data. <i>International Journal of Cardiology</i> , 2020, 315, 59-66.	0.8	10
123	Evaluating biomarkers as predictors of cancer therapy cardiotoxicity: all you need is a meta-analysis?. Letter regarding the article "Troponins and brain natriuretic peptides for the prediction of cardiotoxicity in cancer patients: a meta-analysis." <i>European Journal of Heart Failure</i> , 2020, 22, 1284-1285.	2.9	0
124	A dialogue between the editor-in-chief and a deputy editor of a cardiology journal during the coronavirus outbreak: Take-home messages from the Italian experience. <i>European Journal of Preventive Cardiology</i> , 2020, 27, 790-792.	0.8	3
125	Cardiovascular Death Risk in Recovered Mid-Range Ejection Fraction Heart Failure: Insights From Cardiopulmonary Exercise Test. <i>Journal of Cardiac Failure</i> , 2020, 26, 932-943.	0.7	8
126	Cardiac sympathetic denervation in wild-type transthyretin amyloidosis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2020, 27, 237-243.	1.4	10

#	ARTICLE	IF	CITATIONS
127	Prevalence and prognostic impact of nonischemic late gadolinium enhancement in stress cardiac magnetic resonance. <i>Journal of Cardiovascular Medicine</i> , 2020, 21, 980-985.	0.6	1
128	Deep learning to diagnose cardiac amyloidosis from cardiac magnetic resonance findings. <i>European Heart Journal Supplements</i> , 2020, 22, N116-N130.	0.0	1
129	Echocardiography vs. computed tomography and cardiac magnetic resonance for the detection of left heart thrombosis: a systematic review and meta-analysis. <i>European Heart Journal Supplements</i> , 2020, 22, N28-N44.	0.0	0
130	Unilateral Adrenal Hyperplasia in the Presence of a Reninoma in a Young Pregnant Woman. <i>American Journal of the Medical Sciences</i> , 2020, 360, 607-609.	0.4	0
131	Imaging, Biomarker, and Clinical Predictors of Cardiac Remodeling in Heart Failure With Reduced Ejection Fraction. <i>JACC: Heart Failure</i> , 2019, 7, 782-794.	1.9	113
132	sST2 for Outcome Prediction in Acute Heart Failure. <i>Journal of the American College of Cardiology</i> , 2019, 74, 478-479.	1.2	7
133	The ST2-SCD score and the conundrum of sudden death prediction in heart failure. <i>International Journal of Cardiology</i> , 2019, 294, 50-51.	0.8	1
134	Association between blood pressure variability, cardiovascular disease and mortality in type 2 diabetes: A systematic review and meta-analysis. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 2587-2598.	2.2	63
135	Prognostic Role of Late Gadolinium Enhancement in Patients With Hypertrophic Cardiomyopathy and Low-to-Intermediate Sudden Cardiac Death Risk Score. <i>American Journal of Cardiology</i> , 2019, 124, 1286-1292.	0.7	38
136	Contribution of the Lung to the Genesis of Cheyne-Stokes Respiration in Heart Failure: Plant Gain Beyond Chemoreflex Gain and Circulation Time. <i>Journal of the American Heart Association</i> , 2019, 8, e012419.	1.6	28
137	Clinical and Prognostic Significance of sST2 in Heart Failure. <i>Journal of the American College of Cardiology</i> , 2019, 74, 2193-2203.	1.2	110
138	Impact of Simulated Hyperventilation and Periodic Breathing on Sympatho-Vagal Balance and Hemodynamics in Patients with and without Heart Failure. <i>Respiration</i> , 2019, 98, 482-494.	1.2	8
139	Sympathetic and renin-angiotensin-aldosterone system activation in heart failure with preserved, mid-range and reduced ejection fraction. <i>International Journal of Cardiology</i> , 2019, 296, 91-97.	0.8	60
140	Targeting social disadvantage to prevent early development of heart failure. <i>International Journal of Cardiology</i> , 2019, 293, 181-182.	0.8	1
141	Central and Obstructive Apneas in Heart Failure With Reduced, Mid-Range and Preserved Ejection Fraction. <i>Frontiers in Cardiovascular Medicine</i> , 2019, 6, 125.	1.1	25
142	Noncardiac Versus Cardiac Mortality in Heart Failure With Preserved, Midrange, and Reduced Ejection Fraction. <i>Journal of the American Heart Association</i> , 2019, 8, e013441.	1.6	62
143	Sacubitril/Valsartan, Cardiac Fibrosis, and Remodeling in Heart Failure. <i>Journal of the American College of Cardiology</i> , 2019, 73, 3038-3039.	1.2	8
144	The importance of breathing not properly: Chronic obstructive pulmonary disease as a risk factor for rehospitalization in heart failure. <i>International Journal of Cardiology</i> , 2019, 290, 127-128.	0.8	0

#	ARTICLE	IF	CITATIONS
145	Revisiting the obesity paradox in heart failure: Per cent body fat as predictor of biomarkers and outcome. <i>European Journal of Preventive Cardiology</i> , 2019, 26, 1751-1759.	0.8	28
146	Admission high-sensitivity troponin T and NT-proBNP for outcome prediction in acute heart failure. <i>International Journal of Cardiology</i> , 2019, 293, 137-142.	0.8	24
147	No Aldosterone Breakthrough With the Neprilysin Inhibitor Sacubitril. <i>Journal of the American College of Cardiology</i> , 2019, 73, 3037-3038.	1.2	5
148	Treatment of cardiac transthyretin amyloidosis: an update. <i>European Heart Journal</i> , 2019, 40, 3699-3706.	1.0	121
149	Longer sleep duration and poor sleep quality as risk factors for hyperlipidaemia. <i>European Journal of Preventive Cardiology</i> , 2019, 26, 1285-1287.	0.8	3
150	Cardiac Magnetic Resonance Evaluation of Pulmonary Transit Time and Blood Volume in Adult Congenital Heart disease. <i>Journal of Magnetic Resonance Imaging</i> , 2019, 50, 779-786.	1.9	14
151	Relative hypochromia in acute heart failure to predict outcome and guide treatment: Ready for prime time?. <i>International Journal of Cardiology</i> , 2019, 286, 111-112.	0.8	0
152	Race/ethnicity and plasma NT-proBNP in black and white individuals: How it matters. <i>International Journal of Cardiology</i> , 2019, 286, 164-165.	0.8	0
153	Meta-Analysis of the Prognostic Role of Late Gadolinium Enhancement and Global Systolic Impairment in Left Ventricular Noncompaction. <i>JACC: Cardiovascular Imaging</i> , 2019, 12, 2141-2151.	2.3	84
154	Cheyne-Stokes respiration related oscillations in cardiopulmonary hemodynamics in patients with heart failure. <i>International Journal of Cardiology</i> , 2019, 289, 76-82.	0.8	21
155	The analysis of left atrial function predicts the severity of functional impairment in chronic heart failure: The FLASH multicenter study. <i>International Journal of Cardiology</i> , 2019, 286, 87-91.	0.8	27
156	Cardiac troponins as biomarkers for cardiac disease. <i>Biomarkers in Medicine</i> , 2019, 13, 325-330.	0.6	28
157	Cardiac and Neuromuscular Features of Patients With LMNA-Related Cardiomyopathy. <i>Annals of Internal Medicine</i> , 2019, 171, 458.	2.0	33
158	Exercise oscillatory ventilation and prognosis in heart failure patients with reduced and mid-range ejection fraction. <i>European Journal of Heart Failure</i> , 2019, 21, 1586-1595.	2.9	24
159	Extracellular Volume in Dilated Cardiomyopathy. <i>JACC: Cardiovascular Imaging</i> , 2019, 12, 2586-2587.	2.3	0
160	Letter by Aimo et al Regarding Article, "Development and Validation of a New Risk Prediction Score for Life-Threatening Ventricular Tachyarrhythmias in Laminopathies". <i>Circulation</i> , 2019, 140, e816-e817.	1.6	0
161	Baseline features of the VICTORIA (Vericiguat Global Study in Subjects with Heart Failure with) Tj ETQq1 1 0.784314 rgBT /Overlock 10 2.9 65	0.784314	10
162	What Is Hidden Behind Inferior Negative T Waves. <i>JACC: Case Reports</i> , 2019, 1, 657-662.	0.3	1

#	ARTICLE	IF	CITATIONS
163	Rituximab as a novel treatment for heart failure: evidence from a case series. <i>European Heart Journal - Case Reports</i> , 2019, 3, 1-2.	0.3	3
164	Polymorphisms in the <i>eNOS</i> gene and the risk of coronary artery disease: Making the case for genome-wide association studies. <i>European Journal of Preventive Cardiology</i> , 2019, 26, 157-159.	0.8	4
165	Heart failure prognosis over time: how the prognostic role of oxygen consumption and ventilatory efficiency during exercise has changed in the last 20 years. <i>European Journal of Heart Failure</i> , 2019, 21, 208-217.	2.9	60
166	Behind enemy lines: How to enlarge heart transplant criteria. <i>International Journal of Cardiology</i> , 2019, 277, 104-105.	0.8	0
167	High-sensitivity troponin T, NT-proBNP and glomerular filtration rate: A multimarker strategy for risk stratification in chronic heart failure. <i>International Journal of Cardiology</i> , 2019, 277, 166-172.	0.8	32
168	Beta-blockers: A real antidote for cocaine-related heart disease?. <i>International Journal of Cardiology</i> , 2019, 277, 198-199.	0.8	1
169	Accuracy of ^{99m} Tc-Hydroxymethylene diphosphonate scintigraphy for diagnosis of transthyretin cardiac amyloidosis. <i>Journal of Nuclear Cardiology</i> , 2019, 26, 497-504.	1.4	64
170	Statins during daptomycin therapy: to give or not to give?. <i>Minerva Anestesiologica</i> , 2019, 85, 689-690.	0.6	5
171	High-risk NSTEMI due to subclavian artery atherothrombosis in a prior coronary artery bypass graft patient. <i>Journal of Cardiovascular Echography</i> , 2019, 29, 86.	0.1	0
172	Exercise intolerance in heart failure with preserved ejection fraction: A reappraisal of central mechanisms?. <i>International Journal of Cardiology</i> , 2018, 254, 248-249.	0.8	2
173	Underprescription of disease-modifying drugs in chronic heart failure: More is better?. <i>International Journal of Cardiology</i> , 2018, 254, 242-243.	0.8	1
174	Mineralocorticoid receptor antagonists for heart failure: a real-life observational study. <i>ESC Heart Failure</i> , 2018, 5, 267-274.	1.4	13
175	SYMPATHETIC RENAL DENERVATION AFTER ACUTE MYOCARDIAL INFARCTION BLUNTS ADRENERGIC ACTIVATION AND INCREASED MYOCARDIAL SALVAGE IN PIGS. <i>Journal of the American College of Cardiology</i> , 2018, 71, A175.	1.2	0
176	Sex-related differences in chronic heart failure. <i>International Journal of Cardiology</i> , 2018, 255, 145-151.	0.8	41
177	Natriuretic peptides. D'où venons-nous? Où allons-nous?. <i>International Journal of Cardiology</i> , 2018, 254, 256-257.	0.8	2
178	Prognostic Value of High-Sensitivity Troponin T in Chronic Heart Failure. <i>Circulation</i> , 2018, 137, 286-297.	1.6	157
179	A mechanistic look at sacubitril/valsartan action. Unravelling magician's secrets. <i>International Journal of Cardiology</i> , 2018, 258, 203-204.	0.8	0
180	The importance of integrated left atrial evaluation: From hypertension to heart failure with preserved ejection fraction. <i>International Journal of Clinical Practice</i> , 2018, 72, e13050.	0.8	18

#	ARTICLE	IF	CITATIONS
181	Arterial hypertension and atrial fibrillation. <i>Journal of Cardiovascular Medicine</i> , 2018, 19, 51-61.	0.6	4
182	Postmortem cardiac magnetic resonance in sudden cardiac death. <i>Heart Failure Reviews</i> , 2018, 23, 651-665.	1.7	19
183	High-Sensitivity Troponins and Prognosis in Heart Failure. <i>JACC: Heart Failure</i> , 2018, 6, 440-441.	1.9	0
184	N-terminal fraction of pro-B-type natriuretic peptide versus clinical risk scores for prognostic stratification in chronic systolic heart failure. <i>European Journal of Preventive Cardiology</i> , 2018, 25, 889-895.	0.8	12
185	Wet is bad: Residual congestion predicts worse prognosis in acute heart failure. <i>International Journal of Cardiology</i> , 2018, 258, 201-202.	0.8	6
186	The Barthel Index in elderly acute heart failure patients. Frailty matters. <i>International Journal of Cardiology</i> , 2018, 254, 240-241.	0.8	9
187	Effect of prolonged fasting and low molecular weight heparin or warfarin therapies on 2-deoxy-2-[18F]-fluoro-D-glucose PET cardiac uptake. <i>Journal of Nuclear Cardiology</i> , 2018, 25, 1364-1371.	1.4	16
188	The prognostic benefit of cardiac resynchronization therapy is greater in concordant vs. discordant left bundle branch block in the Multicenter Automatic Defibrillator Implantation Trial-Cardiac Resynchronization Therapy (MADIT-CRT). <i>Europace</i> , 2018, 20, 794-800.	0.7	7
189	Late gadolinium enhancement as a predictor of functional recovery, need for defibrillator implantation and prognosis in non-ischemic dilated cardiomyopathy. <i>International Journal of Cardiology</i> , 2018, 250, 195-200.	0.8	37
190	Implantable cardioverter-defibrillator "computed respiratory disturbance index accurately identifies severe sleep apnea: The DASAP-HF study. <i>Heart Rhythm</i> , 2018, 15, 211-217.	0.3	16
191	Multiparametric prognostic scores in chronic heart failure with reduced ejection fraction: a long-term comparison. <i>European Journal of Heart Failure</i> , 2018, 20, 700-710.	2.9	84
192	β -Glutamyltransferase Fractions in Obese Subjects with Type 2 Diabetes: Relation to Insulin Sensitivity and Effects of Bariatric Surgery. <i>Obesity Surgery</i> , 2018, 28, 1363-1371.	1.1	8
193	Noncardiovascular death after acute heart failure. Do not lose the war while fighting for the failing heart. <i>International Journal of Cardiology</i> , 2018, 250, 231-232.	0.8	1
194	Heart, kidney and FGF23: Les liaisons dangereuses. <i>International Journal of Cardiology</i> , 2018, 253, 120-121.	0.8	1
195	Magnetic Resonance Imaging Correlates of Left Bundle Branch Disease in Patients With Nonischemic Cardiomyopathy. <i>American Journal of Cardiology</i> , 2018, 121, 370-376.	0.7	8
196	Myocardial 123I-metaiodobenzylguanidine imaging in hypertension and left ventricular hypertrophy. <i>Journal of Nuclear Cardiology</i> , 2018, 25, 461-470.	1.4	1
197	sST2 Predicts Outcome in Chronic Heart Failure Beyond NT-proBNP and High-Sensitivity Troponin T. <i>Journal of the American College of Cardiology</i> , 2018, 72, 2309-2320.	1.2	126
198	Erythrocyte-Inspired Discoidal Polymeric Nanoconstructs Carrying Tissue Plasminogen Activator for the Enhanced Lysis of Blood Clots. <i>ACS Nano</i> , 2018, 12, 12224-12237.	7.3	64

#	ARTICLE	IF	CITATIONS
199	Targeting Inflammation With Nanosized Drug Delivery Platforms in Cardiovascular Diseases: Immune Cell Modulation in Atherosclerosis. <i>Frontiers in Bioengineering and Biotechnology</i> , 2018, 6, 177.	2.0	26
200	Low-Thrombogenicity Mechanical Heart Valves. <i>Journal of the American College of Cardiology</i> , 2018, 72, 1878-1879.	1.2	2
201	TCT-560 Sympathetic Renal Denervation After Acute Myocardial Infarction Results in Increased Myocardial Salvage in Pigs. <i>Journal of the American College of Cardiology</i> , 2018, 72, B225.	1.2	0
202	NT-proBNP prognostic value is maintained in elderly and very elderly patients with chronic systolic heart failure. <i>International Journal of Cardiology</i> , 2018, 271, 324-330.	0.8	27
203	Heart rate response to exercise and prognosis: Does rhythm matter?. <i>European Journal of Preventive Cardiology</i> , 2018, 25, 1632-1633.	0.8	1
204	Therapies for cardiac light chain amyloidosis: An update. <i>International Journal of Cardiology</i> , 2018, 271, 152-160.	0.8	31
205	Tireless cardiologists needed for (very) tired patients: The case of heart failure. <i>European Journal of Preventive Cardiology</i> , 2018, 25, 1702-1703.	0.8	0
206	Prognostic Role of Cardiac Magnetic Resonance in Arrhythmogenic Right Ventricular Cardiomyopathy. <i>American Journal of Cardiology</i> , 2018, 122, 1745-1753.	0.7	28
207	Aspirin and Prognosis in Heart Failure. <i>JACC: Heart Failure</i> , 2018, 6, 538-539.	1.9	0
208	The IL-33/ST2 pathway, inflammation and atherosclerosis: Trigger and target?. <i>International Journal of Cardiology</i> , 2018, 267, 188-192.	0.8	40
209	Quality of life and outcome in heart failure with preserved ejection fraction: When sex matters. <i>International Journal of Cardiology</i> , 2018, 267, 141-142.	0.8	6
210	The bottleneck of cardiac rehabilitation for patients with coronary artery disease: How to overcome. <i>European Journal of Preventive Cardiology</i> , 2018, 25, 1239-1241.	0.8	4
211	Is fat good for arrhythmias in ischemic heart failure? Another face of the obesity paradox. <i>International Journal of Cardiology</i> , 2018, 265, 169-170.	0.8	0
212	Dose-dependent efficacy of β -blocker in patients with chronic heart failure and atrial fibrillation. <i>International Journal of Cardiology</i> , 2018, 273, 141-146.	0.8	13
213	Building medical knowledge from real world registries: The case of heart failure. <i>IJC Heart and Vasculature</i> , 2018, 19, 98-99.	0.6	4
214	The CARPEDIEM Algorithm: A Rule-Based System for Identifying Heart Failure Phenotype with a Precision Public Health Approach. <i>Frontiers in Public Health</i> , 2018, 6, 6.	1.3	11
215	Healthy hearts at hectic pace: From daily life stress to abnormal cardiomyocyte function and arrhythmias. <i>European Journal of Preventive Cardiology</i> , 2018, 25, 1419-1430.	0.8	11
216	Role of right ventricular involvement in acute myocarditis, assessed by cardiac magnetic resonance. <i>International Journal of Cardiology</i> , 2018, 271, 359-365.	0.8	33

#	ARTICLE	IF	CITATIONS
217	Left ventricular ejection fraction for risk stratification in chronic systolic heart failure. <i>International Journal of Cardiology</i> , 2018, 273, 136-140.	0.8	11
218	The paradox of low B-type natriuretic peptide levels in obesity revisited: does sex matter?. <i>European Journal of Heart Failure</i> , 2018, 20, 1215-1216.	2.9	6
219	Heart & kidney failure: Who's afraid of renin angiotensin system blockade?. <i>International Journal of Cardiology</i> , 2018, 266, 195-196.	0.8	0
220	Breathing Not Properly in the oldest old. Is brain natriuretic peptide a poor test for the diagnosis of heart failure in the elderly. <i>European Journal of Heart Failure</i> , 2017, 19, 549-551.	2.9	1
221	Prognostic role of β -blocker selectivity and dosage regimens in heart failure patients. Insights from the MECKI score database. <i>European Journal of Heart Failure</i> , 2017, 19, 904-914.	2.9	28
222	Autonomic, functional, skeletal muscle, and cardiac abnormalities are associated with increased ergoreflex sensitivity in mitochondrial disease. <i>European Journal of Heart Failure</i> , 2017, 19, 1701-1709.	2.9	18
223	Meta-Analysis of Soluble Suppression of Tumorigenicity-2 and Prognosis in Acute Heart Failure. <i>JACC: Heart Failure</i> , 2017, 5, 287-296.	1.9	104
224	Predicting readmissions after hospitalization for heart failure: Medical reasoning vs calculators. <i>International Journal of Cardiology</i> , 2017, 236, 348-349.	0.8	0
225	PET-CT evaluation of amyloid systemic involvement with [18F]-florbetaben in patient with proved cardiac amyloidosis: a case report. <i>Journal of Nuclear Cardiology</i> , 2017, 24, 2025-2029.	1.4	11
226	Echocardiographic assessment of pediatric semilunar valve disease. <i>Echocardiography</i> , 2017, 34, 1360-1370.	0.3	10
227	Effect of Sex on Reverse Remodeling in Chronic Systolic Heart Failure. <i>JACC: Heart Failure</i> , 2017, 5, 735-742.	1.9	30
228	Are big data on myocardial infarction enough for small heart failure patients? Lessons from a national registry. <i>International Journal of Cardiology</i> , 2017, 248, 278-279.	0.8	1
229	Prognostic Significance of Central Apneas Throughout a 24-Hour Period in Patients With Heart Failure. <i>Journal of the American College of Cardiology</i> , 2017, 70, 1351-1364.	1.2	51
230	Neurohormonal modulation for treatment of cardiac involvement in dystrophinopathies and mitochondrial disease. <i>European Journal of Preventive Cardiology</i> , 2017, 24, 1718-1724.	0.8	6
231	How to take arms against central apneas in heart failure. <i>Expert Review of Cardiovascular Therapy</i> , 2017, 15, 743-755.	0.6	4
232	N-terminal fragment of B-type natriuretic peptide predicts coexisting subclinical heart and vessel disease. <i>Journal of Cardiovascular Medicine</i> , 2017, 18, 750-757.	0.6	2
233	Cardiac light-chain deposition disease relapsing in the transplanted heart. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2017, 24, 135-137.	1.4	4
234	Prognostic Value of Soluble Suppression of Tumorigenicity-2 in Chronic Heart Failure. <i>JACC: Heart Failure</i> , 2017, 5, 280-286.	1.9	127

#	ARTICLE	IF	CITATIONS
235	Heart failure and anemia: Effects on prognostic variables. <i>European Journal of Internal Medicine</i> , 2017, 37, 56-63.	1.0	33
236	Aortic elasticity indices by magnetic resonance predict progression of ascending aorta dilation. <i>European Radiology</i> , 2017, 27, 1395-1403.	2.3	19
237	ANMCO/ELAS/SIBioC Consensus Document: biomarkers in heart failure. <i>European Heart Journal Supplements</i> , 2017, 19, D102-D112.	0.0	13
238	High sensitivity troponin might be a marker of subclinical scleroderma heart involvement: a preliminary study. <i>Journal of Scleroderma and Related Disorders</i> , 2017, 2, 183-187.	1.0	12
239	And now what to do?™ Direct surgical trans-atrial endocardial pacing electrode implantation in a very complex situation. <i>Europace</i> , 2016, 19, euw171.	0.7	1
240	Prognostic Impact of QRS Axis Deviation in Patients Treated With Cardiac Resynchronization Therapy. <i>Journal of Cardiovascular Electrophysiology</i> , 2016, 27, 315-320.	0.8	18
241	ST segment/heart rate hysteresis improves the diagnostic accuracy of ECG stress test for coronary artery disease in patients with left ventricular hypertrophy. <i>European Journal of Preventive Cardiology</i> , 2016, 23, 1632-1639.	0.8	6
242	The search for efficient diagnostic and prognostic biomarkers of heart failure. <i>Future Cardiology</i> , 2016, 12, 327-337.	0.5	1
243	Cheyne-Stokes Respiration, Chemoreflex, and Ticagrelor-Related Dyspnea. <i>New England Journal of Medicine</i> , 2016, 375, 1004-1006.	13.9	36
244	Usefulness of late gadolinium enhancement MRI combined with stress imaging in predictive significant coronary stenosis in new-diagnosed left ventricular dysfunction. <i>International Journal of Cardiology</i> , 2016, 224, 337-342.	0.8	8
245	Natriuretic peptides as biomarkers of cardiac endocrine function in heart failure: new challenges and perspectives. <i>Future Cardiology</i> , 2016, 12, 573-584.	0.5	11
246	Usefulness of Combined Functional Assessment by Cardiac Magnetic Resonance and Tissue Characterization Versus Task Force Criteria for Diagnosis of Arrhythmogenic Right Ventricular Cardiomyopathy. <i>American Journal of Cardiology</i> , 2016, 118, 1730-1736.	0.7	47
247	Influence of central apneas and chemoreflex activation on pulmonary artery pressure in chronic heart failure. <i>International Journal of Cardiology</i> , 2016, 202, 200-206.	0.8	24
248	The heart after idarubicin overdose. Cardiac death in a patient with acute promyelocytic leukaemia. <i>International Journal of Cardiology</i> , 2016, 203, 997-999.	0.8	3
249	Inhibition of Galectin-3 Pathway Prevents Isoproterenol-Induced Left Ventricular Dysfunction and Fibrosis in Mice. <i>Hypertension</i> , 2016, 67, 606-612.	1.3	90
250	Sex Profile and Risk Assessment With Cardiopulmonary Exercise Testing in Heart Failure: Propensity Score Matching for Sex Selection Bias. <i>Canadian Journal of Cardiology</i> , 2016, 32, 754-759.	0.8	19
251	The metabolic exercise test data combined with Cardiac And Kidney Indexes (MECKI) score and prognosis in heart failure. A validation study. <i>International Journal of Cardiology</i> , 2016, 203, 1067-1072.	0.8	36
252	N-terminal pro-B-type natriuretic peptide is a marker of vascular remodelling and subclinical atherosclerosis in asymptomatic hypertensives. <i>European Journal of Preventive Cardiology</i> , 2016, 23, 366-376.	0.8	16

#	ARTICLE	IF	CITATIONS
253	Prediction of the Chemoreflex Gain by Common Clinical Variables in Heart Failure. PLoS ONE, 2016, 11, e0153510.	1.1	7
254	Targeting Mitochondrial Dysfunction in Chronic Heart Failure: Current Evidence and Potential Approaches. Current Pharmaceutical Design, 2016, 22, 4807-4822.	0.9	16
255	Renal Function and Peak Exercise Oxygen Consumption in Chronic Heart Failure With Reduced Left Ventricular Ejection Fraction. Circulation Journal, 2015, 79, 583-591.	0.7	29
256	Refractory hyperaldosteronism in heart failure is associated with plasma renin activity and angiotensinogen polymorphism. Journal of Cardiovascular Medicine, 2015, 16, 416-422.	0.6	12
257	Glycosylated haemoglobin is associated with neurohormonal activation and poor outcome in chronic heart failure patients with mild left ventricular systolic dysfunction. Journal of Cardiovascular Medicine, 2015, 16, 423-430.	0.6	4
258	Prognostic significance of myocardial extracellular volume fraction in nonischemic dilated cardiomyopathy. Journal of Cardiovascular Medicine, 2015, 16, 681.	0.6	61
259	Cardioprotection by remote ischemic conditioning: Mechanisms and clinical evidences. World Journal of Cardiology, 2015, 7, 621.	0.5	31
260	Prognostic role of atrial fibrillation in patients affected by chronic heart failure. Data from the MECKI score research group. European Journal of Internal Medicine, 2015, 26, 515-520.	1.0	16
261	Galectin-3 and myocardial fibrosis in nonischemic dilated cardiomyopathy. International Journal of Cardiology, 2015, 184, 96-100.	0.8	60
262	Defining phenotypes and disease progression in sarcomeric cardiomyopathies: contemporary role of clinical investigations. Cardiovascular Research, 2015, 105, 409-423.	1.8	66
263	State of the art of aldosterone immunoassays. A multicenter collaborative study on the behalf of the Cardiovascular Biomarkers Study Group of the Italian Section of European Society of Ligand Assay (ELAS) and Societ� Italiana di Biochimica Clinica (SIBIOC). Clinica Chimica Acta, 2015, 444, 106-112.	0.5	22
264	Usefulness of High-Sensitive Troponin Elevation After Effort Stress to Unveil Vulnerable Myocardium in Patients With Heart Failure. American Journal of Cardiology, 2015, 116, 567-572.	0.7	9
265	Renal denervation in resistant arterial hypertension: Effects on neurohormonal activation and cardiac natriuretic peptides. International Journal of Cardiology, 2015, 184, 574-575.	0.8	1
266	Role of tissue characterization by Cardiac Magnetic Resonance in the diagnosis of constrictive pericarditis. International Journal of Cardiovascular Imaging, 2015, 31, 1021-1031.	0.7	17
267	After the SERVE-HF Trial, Is There Still a Need for Treatment of Central Apnea?. Journal of Cardiac Failure, 2015, 21, 903-905.	0.7	15
268	Self-Inserted Needles in the Heart. American Journal of Cardiology, 2015, 116, 1315-1317.	0.7	6
269	Deceptive meaning of oxygen uptake measured at the anaerobic threshold in patients with systolic heart failure and atrial fibrillation. European Journal of Preventive Cardiology, 2015, 22, 1046-1055.	0.8	32
270	Markers of fibrosis, inflammation, and remodeling pathways in heart failure. Clinica Chimica Acta, 2015, 443, 29-38.	0.5	70

#	ARTICLE	IF	CITATIONS
271	Biomarkers of activation of renin-angiotensin-aldosterone system in heart failure: how useful, how feasible?. <i>Clinica Chimica Acta</i> , 2015, 443, 85-93.	0.5	22
272	Cardiac biomarker testing in the clinical laboratory: Where do we stand? General overview of the methodology with special emphasis on natriuretic peptides. <i>Clinica Chimica Acta</i> , 2015, 443, 17-24.	0.5	75
273	The calculation of the cardiac troponin T 99th percentile of the reference population is affected by age, gender, and population selection: A multicenter study in Italy. <i>Clinica Chimica Acta</i> , 2015, 438, 376-381.	0.5	80
274	Peripheral reflex feedbacks in chronic heart failure: Is it time for a direct treatment?. <i>World Journal of Cardiology</i> , 2015, 7, 824.	0.5	5
275	Gamma-Glutamyltransferase Fractions in Human Plasma and Bile: Characteristic and Biogenesis. <i>PLoS ONE</i> , 2014, 9, e88532.	1.1	34
276	Abnormal T2-STIR Magnetic Resonance in Hypertrophic Cardiomyopathy: A Marker of Advanced Disease and Electrical Myocardial Instability. <i>PLoS ONE</i> , 2014, 9, e111366.	1.1	45
277	Correction of procedural arterial pseudoaneurysms: established and novel procedures. <i>Expert Review of Cardiovascular Therapy</i> , 2014, 12, 843-850.	0.6	3
278	Effects of smoking in patients treated with cardiac resynchronization therapy. <i>Internal and Emergency Medicine</i> , 2014, 9, 311-318.	1.0	0
279	Amino Terminal Fragment of Pro-B-Type Natriuretic Peptide for Complex Congenital Heart Diseases. <i>Journal of the American College of Cardiology</i> , 2014, 63, 1342-1343.	1.2	2
280	Cocaine assumption and transient myocardial edema in asymptomatic cocaine heavy-users. <i>International Journal of Cardiology</i> , 2014, 173, 614-615.	0.8	9
281	Myocardial signal intensity decay after gadolinium injection: a fast and effective method for the diagnosis of cardiac amyloidosis. <i>International Journal of Cardiovascular Imaging</i> , 2014, 30, 1105-1115.	0.7	23
282	CHADS2 and CHA2DS2-VASc scores to predict morbidity and mortality in heart failure patients candidates to cardiac resynchronization therapy. <i>Europace</i> , 2014, 16, 71-80.	0.7	64
283	Troponins in cardiac amyloidosis: multipurpose markers. <i>Nature Reviews Cardiology</i> , 2014, 11, 179-179.	6.1	8
284	Incremental Prognostic Value of Myocardial Fibrosis in Patients With Non-Ischemic Cardiomyopathy Without Congestive Heart Failure. <i>Circulation: Heart Failure</i> , 2014, 7, 448-456.	1.6	94
285	b-Gamma-glutamyltransferase activity in human vulnerable carotid plaques. <i>Atherosclerosis</i> , 2014, 237, 307-313.	0.4	24
286	Circulating gamma-glutamyltransferase fractions in cirrhosis. <i>Liver International</i> , 2014, 34, e191-9.	1.9	8
287	Targeting Periodic Breathing in Heart Failure Patients, and Treating It Gently. <i>Journal of Cardiac Failure</i> , 2014, 20, 289-291.	0.7	4
288	Surgery Casualties. <i>Journal of the American College of Cardiology</i> , 2014, 63, 181-183.	1.2	2

#	ARTICLE	IF	CITATIONS
289	Can We Measure How Hot the Plaque Is? Not Yet, Butâ€¦. Journal of the American College of Cardiology, 2013, 62, 338-339.	1.2	1
290	Influence of preload and afterload on stroke volume response to low-dose dobutamine stress in patients with non-ischemic heart failure: A cardiac MR study. International Journal of Cardiology, 2013, 166, 475-481.	0.8	8
291	Prognostic Value of Indeterminable Anaerobic Threshold in Heart Failure. Circulation: Heart Failure, 2013, 6, 977-987.	1.6	60
292	Myocardial Fibrosis as a Key Determinant of Left Ventricular Remodeling in Idiopathic Dilated Cardiomyopathy. Circulation: Cardiovascular Imaging, 2013, 6, 790-799.	1.3	132
293	Correlates and reference limits of plasma gamma-glutamyltransferase fractions from the Framingham Heart Study. Clinica Chimica Acta, 2013, 417, 19-25.	0.5	35
294	A simple method for measuring baroreflex sensitivity holds prognostic value in heart failure. International Journal of Cardiology, 2013, 169, e9-e11.	0.8	12
295	Forced expiratory volume in one second: Prognostic value in systolic heart failure. International Journal of Cardiology, 2013, 168, 1573-1574.	0.8	7
296	Metabolic exercise test data combined with cardiac and kidney indexes, the MECKI score: A multiparametric approach to heart failure prognosis. International Journal of Cardiology, 2013, 167, 2710-2718.	0.8	183
297	CMR-Verified Interstitial Myocardial Fibrosis as a Marker of Subclinical Cardiac Involvement in LMNA Mutation Carriers. JACC: Cardiovascular Imaging, 2013, 6, 124-126.	2.3	38
298	Severe heart failure prognosis evaluation for transplant selection in the era of beta-blockers: Role of peak oxygen consumption. International Journal of Cardiology, 2013, 168, 5078-5081.	0.8	25
299	B-Type Natriuretic Peptide Assay for Complex Congenital Heart Diseases. Journal of the American College of Cardiology, 2013, 61, 2022-2023.	1.2	1
300	Prognostic value of plasma renin activity in heart failure patients with chronic kidney disease. International Journal of Cardiology, 2013, 167, 711-715.	0.8	27
301	Breathless Heart. Journal of the American College of Cardiology, 2013, 61, 1167-1168.	1.2	2
302	High-sensitivity gamma-glutamyltransferase fraction pattern in alcohol addicts and abstainers. Drug and Alcohol Dependence, 2013, 127, 239-242.	1.6	21
303	Daptomycin Concentrations in Valve Tissue and Vegetation in Patients with Bacterial Endocarditis. Antimicrobial Agents and Chemotherapy, 2013, 57, 601-602.	1.4	20
304	B-Type Natriuretic Peptides Are a Marker for Congenital Heart Disease in Neonates. Pediatric Critical Care Medicine, 2013, 14, 438-439.	0.2	6
305	Response to Letters Regarding Article, "Myocardial Fibrosis as a Key Determinant of Left Ventricular Remodeling in Idiopathic Dilated Cardiomyopathy: A Contrast-Enhanced Cardiovascular Magnetic Study". Circulation: Cardiovascular Imaging, 2013, 6, e79.	1.3	3
306	Fibrosis and Mortality in Patients With Dilated Cardiomyopathy. JAMA - Journal of the American Medical Association, 2013, 309, 2547.	3.8	6

#	ARTICLE	IF	CITATIONS
307	Reference values for urinary neutrophil gelatinase-associated lipocalin (NGAL) in pediatric age measured with a fully automated chemiluminescent platform. <i>Clinical Chemistry and Laboratory Medicine</i> , 2013, 51, 1101-5.	1.4	28
308	Microvascular responses to aldosterone in hamster cheek pouch microcirculation. <i>Clinical Hemorheology and Microcirculation</i> , 2013, 53, 303-315.	0.9	3
309	Effect of acute administration of vitamin C on muscle sympathetic activity, cardiac sympathovagal balance, and baroreflex sensitivity in hypertensive patients. <i>American Journal of Clinical Nutrition</i> , 2012, 96, 302-308.	2.2	44
310	Developmental variations of plasma gamma-glutamyltransferase fractions in humans and in laboratory mammals. <i>Biomarkers</i> , 2012, 17, 43-47.	0.9	2
311	Accuracy of γ -GGT fraction for the diagnosis of nonalcoholic fatty liver disease. <i>Liver International</i> , 2012, 32, 629-634.	1.9	45
312	Abnormal hyperventilation in patients with hepatic cirrhosis: Role of enhanced chemosensitivity to carbon dioxide. <i>International Journal of Cardiology</i> , 2012, 154, 22-26.	0.8	9
313	Low triiodothyronine and exercise capacity in heart failure. <i>International Journal of Cardiology</i> , 2012, 154, 153-157.	0.8	20
314	Myocardial delayed enhancement in paucisymptomatic nonischemic dilated cardiomyopathy. <i>International Journal of Cardiology</i> , 2012, 157, 43-47.	0.8	51
315	Application of the Seattle Heart Failure Model in Patients on Cardiac Resynchronization Therapy. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2012, 35, 88-94.	0.5	11
316	The paradox of low BNP levels in obesity. <i>Heart Failure Reviews</i> , 2012, 17, 81-96.	1.7	119
317	Natriuretic Peptide Assays Revisited. <i>Journal of the American College of Cardiology</i> , 2011, 57, 1396-1398.	1.2	18
318	The Month After. <i>Journal of the American College of Cardiology</i> , 2011, 58, 1967-1969.	1.2	0
319	When the heart is burning: Amino-terminal pro-brain natriuretic peptide as an early marker of cardiac involvement in active autoimmune rheumatic disease. <i>International Journal of Cardiology</i> , 2011, 148, 161-167.	0.8	17
320	PLASMA RENIN ACTIVITY AND ANGIOTENSINOGEN M235T POLYMORPHISM ARE DETERMINANTS OF ALDOSTERONE ESCAPE IN PATIENTS WITH SYSTOLIC HEART FAILURE. <i>Journal of the American College of Cardiology</i> , 2011, 57, E260.	1.2	0
321	Comparison of NT-proCNP and CNP plasma levels in heart failure, diabetes and cirrhosis patients. <i>Regulatory Peptides</i> , 2011, 166, 15-20.	1.9	33
322	Effect of Acetazolamide on Chemosensitivity, Cheyne-Stokes Respiration, and Response to Effort in Patients With Heart Failure. <i>American Journal of Cardiology</i> , 2011, 107, 1675-1680.	0.7	51
323	Prognostic Value of Plasma Renin Activity in Heart Failure. <i>American Journal of Cardiology</i> , 2011, 108, 246-251.	0.7	61
324	B-type natriuretic peptide secretion following scuba diving. <i>Biomarkers in Medicine</i> , 2011, 5, 205-209.	0.6	7

#	ARTICLE	IF	CITATIONS
325	Markers of Arrhythmogenic Risk in Hypertensive Subjects. <i>Current Pharmaceutical Design</i> , 2011, 17, 3062-3073.	0.9	8
326	Serum gamma-glutamyltransferase fractions in Myotonic Dystrophy type I: Differences with healthy subjects and patients with liver disease. <i>Clinical Biochemistry</i> , 2010, 43, 1246-1248.	0.8	8
327	Sleep Disordered Breathing and Arrhythmia Burden in Pacemaker Recipients. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2010, 33, 1462-1466.	0.5	11
328	Cardiovascular risk factors and $\hat{\Gamma}^3$ -glutamyltransferase fractions in healthy individuals. <i>Clinical Chemistry and Laboratory Medicine</i> , 2010, 48, 713-717.	1.4	32
329	Real-Time Dynamic Carbon Dioxide Administration. <i>Journal of the American College of Cardiology</i> , 2010, 56, 1832-1837.	1.2	45
330	Atrial fibrillation and amino-terminal pro-brain natriuretic peptide as independent predictors of prognosis in systolic heart failure. <i>International Journal of Cardiology</i> , 2010, 140, 344-350.	0.8	11
331	Different Substrates of Non-Sustained Ventricular Tachycardia in Post-infarction Patients With and Without Left Ventricular Dilatation. <i>Journal of Cardiac Failure</i> , 2010, 16, 61-68.	0.7	12
332	Concordant Versus Discordant Left Bundle Branch Block in Heart Failure Patients: Novel Clinical Value of an Old Electrocardiographic Diagnosis. <i>Journal of Cardiac Failure</i> , 2010, 16, 320-326.	0.7	15
333	S38G single-nucleotide polymorphism at the KCNE1 locus is associated with heart failure. <i>Heart Rhythm</i> , 2010, 7, 363-367.	0.3	18
334	Chapter 7 Clinical Relevance of BNP Measurement in the Follow-up of Patients with Chronic Heart Failure. <i>Advances in Clinical Chemistry</i> , 2009, 48, 163-179.	1.8	25
335	Serum $\hat{\Gamma}^3$ -glutamyltransferase: linking together environmental pollution, redox equilibria and progression of atherosclerosis?. <i>Clinical Chemistry and Laboratory Medicine</i> , 2009, 47, 1583-4.	1.4	4
336	Energy Metabolism in the Normal and in the Diabetic Heart. <i>Current Pharmaceutical Design</i> , 2009, 15, 836-840.	0.9	34
337	Old and new biomarkers of heart failure. <i>European Journal of Heart Failure</i> , 2009, 11, 331-335.	2.9	79
338	Prognostic Value of Combined Measurement of Brain Natriuretic Peptide and Triiodothyronine in Heart Failure. <i>Journal of Cardiac Failure</i> , 2009, 15, 35-40.	0.7	53
339	Comparison between analytical performances of polyclonal and monoclonal electrochemiluminescence immunoassays for NT-proBNP. <i>Clinica Chimica Acta</i> , 2009, 400, 70-73.	0.5	63
340	The search for a pathophysiological link between gender, cardiac endocrine function, body mass regulation and cardiac mortality: Proposal for a working hypothesis. <i>Clinica Chimica Acta</i> , 2009, 405, 1-7.	0.5	41
341	Asymmetrical myocardial expression of natriuretic peptides in pacing-induced heart failure. <i>Peptides</i> , 2009, 30, 1710-1713.	1.2	26
342	Additive prognostic value of gamma-glutamyltransferase in coronary artery disease. <i>International Journal of Cardiology</i> , 2009, 136, 80-85.	0.8	53

#	ARTICLE	IF	CITATIONS
343	Risk factors and prognostic value of daytime Cheyne-Stokes respiration in chronic heart failure patients. <i>International Journal of Cardiology</i> , 2009, 137, 47-53.	0.8	63
344	Combined Increased Chemosensitivity to Hypoxia and Hypercapnia as a Prognosticator in Heart Failure. <i>Journal of the American College of Cardiology</i> , 2009, 53, 1975-1980.	1.2	131
345	Cultured human cells release soluble γ -glutamyltransferase complexes corresponding to the plasma b-GGT. <i>Biomarkers</i> , 2009, 14, 486-492.	0.9	26
346	γ -Glutamyltransferase activity in human atherosclerotic plaques—Biochemical similarities with the circulating enzyme. <i>Atherosclerosis</i> , 2009, 202, 119-127.	0.4	108
347	New and emerging biomarkers of heart failure. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2009, 46, 107-128.	2.7	14
348	A high performance gel filtration chromatography method for γ -glutamyltransferase fraction analysis. <i>Analytical Biochemistry</i> , 2008, 374, 1-6.	1.1	58
349	Expression of C-type natriuretic peptide and of its receptor NPR-B in normal and failing heart. <i>Peptides</i> , 2008, 29, 2208-2215.	1.2	66
350	Clinical relevance of measurement of brain natriuretic peptide and N-terminal pro-brain natriuretic peptide in pediatric cardiology. <i>Clinica Chimica Acta</i> , 2008, 390, 12-22.	0.5	35
351	Predictive value of elevated neutrophil-lymphocyte ratio on cardiac mortality in patients with stable coronary artery disease. <i>Clinica Chimica Acta</i> , 2008, 395, 27-31.	0.5	306
352	Fractions of plasma gamma-glutamyltransferase in healthy individuals: Reference values. <i>Clinica Chimica Acta</i> , 2008, 395, 188-189.	0.5	30
353	Distribution of plasma cardiac troponin I values in healthy subjects: pathophysiological considerations. <i>Clinical Chemistry and Laboratory Medicine</i> , 2008, 46, 804-8.	1.4	54
354	Clinical relevance of non-cardiac determinants of natriuretic peptide levels. <i>Clinical Chemistry and Laboratory Medicine</i> , 2008, 46, 1515-23.	1.4	24
355	Natriuretic peptide testing in primary care patients. <i>Clinical Chemistry and Laboratory Medicine</i> , 2008, 46, 1533-42.	1.4	2
356	Permanent atrial fibrillation affects exercise capacity in chronic heart failure patients. <i>European Heart Journal</i> , 2008, 29, 2367-2372.	1.0	73
357	Ventricular Repolarization in Hypertension: Beyond Bazett. <i>American Journal of Hypertension</i> , 2008, 21, 9-9.	1.0	0
358	Awake Blood Pressure Variability, Inflammatory Markers and Target Organ Damage in Newly Diagnosed Hypertension. <i>Hypertension Research</i> , 2008, 31, 2137-2146.	1.5	75
359	Clinical significance of chemosensitivity in chronic heart failure: influence on neurohormonal derangement, Cheyne-Stokes respiration and arrhythmias. <i>Clinical Science</i> , 2008, 114, 489-497.	1.8	98
360	Comparison of the Diagnostic Accuracy of Brain Natriuretic Peptide (BNP) and the N-Terminal Part of the Propeptide of BNP Immunoassays in Chronic and Acute Heart Failure: A Systematic Review. <i>Clinical Chemistry</i> , 2007, 53, 813-822.	1.5	118

#	ARTICLE	IF	CITATIONS
361	Evaluation of Analytical Performance of the Siemens ADVIA TnI Ultra Immunoassay. <i>Clinical Chemistry</i> , 2007, 53, 1722-1723.	1.5	49
362	Influence of Scal and Natriuretic Peptide (NP) Clearance Receptor Polymorphisms of the NP System on NP Concentration in Chronic Heart Failure. <i>Clinical Chemistry</i> , 2007, 53, 1886-1890.	1.5	22
363	Comparison of Brain Natriuretic Peptide (BNP) and Amino-Terminal ProBNP for Early Diagnosis of Heart Failure. <i>Clinical Chemistry</i> , 2007, 53, 1289-1297.	1.5	71
364	The authors of the article cited above respond:. <i>Clinical Chemistry</i> , 2007, 53, 1720-1721.	1.5	3
365	Increased levels of C-type natriuretic peptide in patients with idiopathic left ventricular dysfunction. <i>Peptides</i> , 2007, 28, 1068-1073.	1.2	30
366	Sequencing and cardiac expression of natriuretic peptide receptor 2 (NPR-B) in <i>Sus Scrofa</i> . <i>Peptides</i> , 2007, 28, 1390-1396.	1.2	18
367	Platelet activation, gamma-glutamyltransferase and stent restenosis. <i>Atherosclerosis</i> , 2007, 195, e231-e232.	0.4	4
368	Progressive multifocal leukoencephalopathy in a haploidentical stem cell transplant recipient: A clinical, neuroradiological and virological response after treatment with risperidone. <i>Antiviral Research</i> , 2007, 74, 156-158.	1.9	39
369	\hat{I}^2 -Lipoprotein- and LDL-associated serum \hat{I}^3 -glutamyltransferase in patients with coronary atherosclerosis. <i>Atherosclerosis</i> , 2006, 186, 80-85.	0.4	85
370	Aerobic Training Decreases B-Type Natriuretic Peptide Expression and Adrenergic Activation in Patients With Heart Failure. <i>Journal of the American College of Cardiology</i> , 2006, 47, 1835-1839.	1.2	166
371	Early Activation of an Altered Thyroid Hormone Profile in Asymptomatic or Mildly Symptomatic Idiopathic Left Ventricular Dysfunction. <i>Journal of Cardiac Failure</i> , 2006, 12, 520-526.	0.7	59
372	C-type natriuretic peptide and heart failure. <i>Pharmacological Research</i> , 2006, 54, 326-333.	3.1	29
373	Cardiac production of C-type natriuretic peptide in heart failure. <i>Journal of Cardiovascular Medicine</i> , 2006, 7, 397-399.	0.6	40
374	The Potential Roles of Gamma-Glutamyltransferase Activity in the Progression of Atherosclerosis and Cardiovascular Diseases. <i>Vascular Disease Prevention</i> , 2006, 3, 205-209.	0.2	5
375	Gamma-glutamyltransferase as a cardiovascular risk factor. <i>European Heart Journal</i> , 2006, 27, 2145-2146.	1.0	37
376	Neuro-hormonal activation predicts ventilatory response to exercise and functional capacity in patients with heart failure. <i>European Journal of Heart Failure</i> , 2006, 8, 46-53.	2.9	41
377	Cardiac endocrine function is an essential component of the homeostatic regulation network: physiological and clinical implications. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2006, 290, H17-H29.	1.5	231
378	Clinical relevance of biological variation: the lesson of brain natriuretic peptide (BNP) and NT-proBNP assay. <i>Clinical Chemistry and Laboratory Medicine</i> , 2006, 44, 366-78.	1.4	57

#	ARTICLE	IF	CITATIONS
379	C-type natriuretic peptide plasma levels increase in patients with chronic heart failure as a function of clinical severity. <i>European Journal of Heart Failure</i> , 2005, 7, 1145-1148.	2.9	86
380	Analytical Performance and Diagnostic Accuracy of Immunometric Assays for the Measurement of Plasma B-Type Natriuretic Peptide (BNP) and N-Terminal proBNP. <i>Clinical Chemistry</i> , 2005, 51, 445-447.	1.5	70
381	Comparison of a Fully Automated Immunoassay with a Point-of-Care Testing Method for B-Type Natriuretic Peptide. <i>Clinical Chemistry</i> , 2005, 51, 1274-1276.	1.5	37
382	Clinical Relevance of Biological Variation of B-Type Natriuretic Peptide. <i>Clinical Chemistry</i> , 2005, 51, 925-926.	1.5	28
383	Personality traits and heart rate variability predict long-term cardiac mortality after myocardial infarction. <i>European Heart Journal</i> , 2005, 26, 1612-1617.	1.0	54
384	Gamma-Glutamyltransferase, Atherosclerosis, and Cardiovascular Disease. <i>Circulation</i> , 2005, 112, 2078-2080.	1.6	289
385	Right heart overload contributes to cardiac natriuretic hormone elevation in patients with heart failure. <i>International Journal of Cardiology</i> , 2005, 104, 39-45.	0.8	25
386	Diagnostic Accuracy and Prognostic Relevance of the Measurement of Cardiac Natriuretic Peptides: A Review. <i>Clinical Chemistry</i> , 2004, 50, 33-50.	1.5	307
387	Human Atherosclerotic Plaques Contain Gamma-Glutamyl Transpeptidase Enzyme Activity. <i>Circulation</i> , 2004, 109, 1440-1440.	1.6	172
388	Endocrine Paradox in Heart Failure: Resistance to Biological Effects of Cardiac Natriuretic Hormones. <i>Clinical Chemistry</i> , 2004, 50, 2465-2468.	1.5	12
389	Early assessment of heart rate variability is predictive of in-hospital death and major complications after acute myocardial infarction. <i>International Journal of Cardiology</i> , 2004, 96, 361-368.	0.8	45
390	Abnormal ventricular repolarization in hypertensive patients: role of sympatho-vagal imbalance and left ventricular hypertrophy. <i>International Journal of Cardiology</i> , 2004, 97, 57-62.	0.8	26
391	Natriuretic Peptides (NPs): Automated Electrochemiluminescent Immunoassay for N-Terminal pro-BNP Compared with IRMAs for ANP and BNP in Heart Failure Patients and Healthy Individuals. <i>Clinical Chemistry</i> , 2003, 49, 1552-1554.	1.5	36
392	Serum Gamma-Glutamyltransferase as a Risk Factor of Ischemic Stroke Might Be Independent of Alcohol Consumption. <i>Stroke</i> , 2002, 33, 1163-1164.	1.0	54
393	Hyperinsulinemia and Autonomic Nervous System Dysfunction in Obesity. <i>Circulation</i> , 2001, 103, 513-519.	1.6	209
394	Predictability and nonlinearity of the heart rhythm. <i>Chaos, Solitons and Fractals</i> , 1998, 9, 507-515.	2.5	14
395	704 Recurrence quantification analysis describe the complex and deterministic behavior of heart rate variability in healthy subjects: Link with susceptibility to hypnosis. <i>International Journal of Psychophysiology</i> , 1998, 30, 266.	0.5	0
396	1027 Circulating levels of cardiac natriuretic peptides measured by highly sensitive and specific IRMA methods in normal subjects and in patients with heart failure. <i>American Journal of Hypertension</i> , 1998, 11, 174A.	1.0	1

#	ARTICLE	IF	CITATIONS
397	Improved exercise capacity with acute aminophylline administration in patients with syndrome X. Journal of the American College of Cardiology, 1989, 14, 1450-1453.	1.2	72
398	Improvement of Walking Distance in Patients with Intermittent Claudication by Chronic Local Therapy with Isosorbide Dinitrate Ointment. Angiology, 1988, 39, 1-7.	0.8	4
399	Treatment of end-stage congestive heart failure by extracorporeal ultrafiltration. American Journal of Cardiology, 1987, 59, 379-380.	0.7	33
400	Findings from long-term electrocardiographic monitoring of patients with variant angina in a coronary care unit. American Journal of Cardiology, 1987, 60, 36-39.	0.7	18